Thrombin; Coagulation factor Xa (Thrombin (FIIa), Factor Xa (FXa))

Thrombin is a serine protease (factor IIa) that serves as the final effector in the coagulation cascade, converting fibrinogen into fibrin and activating platelets, leading to thrombus formation[3][8]. Factor Xa is an upstream serine protease generated from factor X and acts as the critical activator of prothrombin (factor II) to thrombin in complex with factor Va at the site of vascular injury[1][7]. Both enzymes are essential for normal hemostasis, and their dysregulation can lead to severe bleeding or thrombotic disorders. They are established therapeutic targets with several approved small-molecule inhibitors (rivaroxaban, apixaban, dabigatran, etc.) used for the prevention and treatment of venous thromboembolism, atrial fibrillation–associated stroke, and other thrombotic conditions. In addition to their classical role in coagulation, both thrombin and factor Xa are involved in cell signaling (particularly via protease-activated receptors), inflammation, and possibly vascular disease progression[9].

Other names

ProthrombinaseCoagulation factor IIaFIIaFXaActivated factor XStuart-Prower factor

Direct inhibition of the active site to block protease activity (e.g., direct thrombin/factor Xa inhibitors) Indirect inhibition via antithrombin enhancement (e.g., heparins, fondaparinux) Inhibition prevents conversion of prothrombin to thrombin (FXa inhibition) or cleavage of fibrinogen to fibrin (thrombin inhibition)